8,535 Shares in CVS Health Corporation $CVS Purchased by Providence First Trust Co

Posted by Stanley Muller on May 6th, 2026

Providence First Trust Co acquired a new stake in CVS Health Corporation (NYSE:CVS – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 8,535 shares of the pharmacy operator’s stock, valued at approximately $677,000.

A number of other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. lifted its position in CVS Health by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after buying an additional 1,824,424 shares in the last quarter. Capital World Investors increased its stake in shares of CVS Health by 2.1% in the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after acquiring an additional 1,419,575 shares during the last quarter. State Street Corp raised its holdings in shares of CVS Health by 0.3% during the 3rd quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock worth $4,443,357,000 after acquiring an additional 149,701 shares during the period. Capital International Investors boosted its position in shares of CVS Health by 1.1% during the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock valued at $2,012,347,000 after acquiring an additional 302,499 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of CVS Health by 3.2% in the third quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after purchasing an additional 760,579 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: CVS Caremark will expand adoption of lower‑cost biosimilars across its commercial formularies effective July 1, preferring interchangeable biosimilars over certain reference brands — a move that should lower drug spend for clients and improve PBM margins. PR Newswire: CVS Caremark Expands Biosimilar Adoption
Positive Sentiment: CVS said it will prefer lower‑cost interchangeable biosimilars over J&J’s Stelara on its main formularies starting July 1 — a direct cost‑management step that can improve margins but may pressure revenues for affected brand drugs. Reuters: CVS to drop J&J’s Stelara
Positive Sentiment: HSBC raised its price target on CVS to $85 (hold), signaling modest analyst confidence in upside tied to the company’s earnings and cost actions. That provides some near‑term support for the stock. MarketScreener: HSBC adjusts price target on CVS
Positive Sentiment: Media and commentators (including Jim Cramer) are expressing optimism that CVS will report a strong quarter, which can buoy sentiment into earnings. InsiderMonkey: Jim Cramer on CVS quarter
Neutral Sentiment: Investor previews and analysts flag Q1 results and cost trends/margins as the main near‑term focus; outcomes on utilization and PBM pricing will determine stock direction after the print. MSN: CVS Q1 earnings preview
Neutral Sentiment: Coverage notes investors are watching cost trends and margins closely in the upcoming earnings release; PBM results and medical cost trajectories will be key. Seeking Alpha: CVS earnings in focus
Neutral Sentiment: Analysts/press point to two hurdles in the quarter (operational/cost execution and broader healthcare demand); Aetna’s strength in Medicare Advantage is a stabilizer but may not fully offset other pressures. Yahoo Finance: Two hurdles to clear
Neutral Sentiment: CVS Health Ventures made a strategic investment in Fathom to accelerate autonomous coding — a longer‑term efficiency play that could reduce administrative costs across the enterprise. Yahoo Finance: Fathom secures investment
Negative Sentiment: An opinion piece questions the CVS affiliation with Mass General Brigham — while the partnership could expand primary‑care access, it raises concerns about costs, care continuity and potential regulatory/competitive scrutiny that could complicate execution and investor sentiment. Boston Globe: CVS affiliation with Mass General Brigham
Neutral Sentiment: Industry retail shakeups (reports of rivals closing stores) highlight tough store economics in some markets — an indirect signal that pharmacy/retail footprint optimization remains relevant for CVS strategy. TheStreet: Competitor store closures

CVS Health Trading Down 1.6%

Shares of NYSE CVS opened at $80.67 on Wednesday. The stock has a fifty day simple moving average of $76.40 and a 200-day simple moving average of $77.96. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $85.15. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $103.39 billion, a PE ratio of 58.46, a PEG ratio of 0.86 and a beta of 0.60.

CVS Health (NYSE:CVS – Get Free Report) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.97 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%. On average, equities analysts forecast that CVS Health Corporation will post 7.14 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio is presently 192.75%.

Wall Street Analyst Weigh In

CVS has been the topic of a number of analyst reports. TD Cowen reaffirmed a “buy” rating on shares of CVS Health in a research note on Friday, March 13th. The Goldman Sachs Group increased their price target on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Leerink Partners reaffirmed an “outperform” rating and set a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. Piper Sandler decreased their price objective on CVS Health from $101.00 to $99.00 and set an “overweight” rating on the stock in a report on Tuesday, March 31st. Finally, Argus lowered their price objective on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, January 28th. Twenty analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $94.61.

View Our Latest Stock Report on CVS

About CVS Health

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.